Bioporto A/S
CSE:BIOPOR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.222
2.965
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Bioporto A/S
Bioporto A/S
Capital Expenditures
Bioporto A/S
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bioporto A/S
CSE:BIOPOR
|
Capital Expenditures
-kr39k
|
CAGR 3-Years
71%
|
CAGR 5-Years
51%
|
CAGR 10-Years
26%
|
|
|
Genmab A/S
CSE:GMAB
|
Capital Expenditures
-kr220m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
-32%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Capital Expenditures
-kr20.5m
|
CAGR 3-Years
-144%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-13%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Capital Expenditures
-€981k
|
CAGR 3-Years
66%
|
CAGR 5-Years
28%
|
CAGR 10-Years
1%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Capital Expenditures
-kr1.1B
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-21%
|
|
|
F
|
Fluoguide AS
STO:FLUO
|
Capital Expenditures
kr0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bioporto A/S
Glance View
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
See Also
What is Bioporto A/S's Capital Expenditures?
Capital Expenditures
-39k
DKK
Based on the financial report for Jun 30, 2024, Bioporto A/S's Capital Expenditures amounts to -39k DKK.
What is Bioporto A/S's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
26%
The average annual Capital Expenditures growth rates for Bioporto A/S have been 71% over the past three years , 51% over the past five years , and 26% over the past ten years .
You don't have any saved screeners yet
